Literature DB >> 9720622

Concentration- and region-dependent intestinal permeability of fluvastatin in the rat.

A Lindahl1, R Sandström, A L Ungell, H Lennernäs.   

Abstract

The purpose of this study was to investigate the mechanisms of transport of fluvastatin across the intestinal mucosa in various regions of the intestine in the rat. In-situ single-pass perfusions of the jejunum, ileum and colon were performed and the effective permeability (Peff) of fluvastatin, antipyrine and D-glucose were assessed in each region, at three different perfusate fluvastatin concentrations (1.6, 16 and 160 microM). The effect of lovastatin acid on the bi-directional transport of fluvastatin across the ileal mucosa was also studied. The Peff of fluvastatin was found to be dependent both on the intestinal region and on the concentration in the intestinal lumen (P < 0.001). Fluvastatin had the lowest Peff (0.55 +/- 0.10 x 10(-4) cm s(-1)) in the jejunum at 1.6 microM, and the highest Peff (1.0 +/- 0.16 x 10(-4) cm s(-1)) in the colon at 160 microM. The highest concentration of fluvastatin increased the average absorption of water from the intestine by 209% (P < 0.05), and the average Peff of D-glucose by 29% (P < 0.05). The presence of excess lovastatin acid (100 microM, compared with fluvastatin 1.6 microM) at the luminal side increased the average absorption of water by 218% (P < 0.001), and the Peff of fluvastatin in the ileum and the colon by 44 and 50%, respectively (P < 0.05). The presence of lovastatin acid on the luminal side in the ileum also increased the blood-to-lumen transport (exsorption) of fluvastatin by 43% (P < 0.001). The increased intestinal absorption of fluvastatin at higher concentrations does not suggest that substantial absorption occurs by any carrier-mediated process in the absorptive direction. The increased bi-directional transport when lovastatin acid was added to the lumen suggests that fluvastatin is not a P-glycoprotein substrate. Instead, the concentration-dependent increase in the absorption of fluvastatin, water and D-glucose suggests a direct effect of fluvastatin on the transcellular passive transport.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720622     DOI: 10.1111/j.2042-7158.1998.tb07134.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat.

Authors:  A Lindahl; S Frid; A L Ungell; H Lennernas
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Clinical pharmacokinetics of fluvastatin.

Authors:  C D Scripture; J A Pieper
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte?

Authors:  Natalie L Trevaskis; Gary Nguyen; Martin J Scanlon; Christopher J H Porter
Journal:  Pharm Res       Date:  2011-04-27       Impact factor: 4.200

4.  Surface activity and concentration dependent intestinal permeability in the rat.

Authors:  A Lindahl; B Persson; A L Ungell; H Lennernäs
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

5.  In Silico Prediction of Intestinal Permeability by Hierarchical Support Vector Regression.

Authors:  Ming-Han Lee; Giang Huong Ta; Ching-Feng Weng; Max K Leong
Journal:  Int J Mol Sci       Date:  2020-05-19       Impact factor: 5.923

6.  Impact of Micellar Vehicles on in situ Intestinal Absorption Properties of Beta-Lapachone in Rats.

Authors:  Soung Baek Jang; Dongju Kim; Seong Yeon Kim; Changhee Park; Ji Hoon Jeong; Hyo-Jeong Kuh; Jaehwi Lee
Journal:  Korean J Physiol Pharmacol       Date:  2013-02-14       Impact factor: 2.016

7.  Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.

Authors:  Helena Buzková; Kristina Pechandová; Vilém Danzig; Tomá Vareka; Frantisek Perlik; Ales Zak; Ondrej Slanar
Journal:  Med Sci Monit       Date:  2012-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.